Section
Agents
13 pages in this section, most recently updated September 4, 2026. Each opens with a plain-English summary and cites its sources.
01 · Agents
FeaturedSemaglutide (Ozempic, Wegovy): mechanism, approvals, dosing, trials and side-effect rates
You'll get: Semaglutide is a weekly shot sold as Ozempic for type 2 diabetes and Wegovy for weight, heart risk and liver disease.
Semaglutide, the weekly shot behind Ozempic and Wegovy: how it works, every FDA approval from 2017 to the 7.2 mg dose, label dosing, trials, side effects.
Updated September 4, 2026
02 · Agents
FeaturedOral semaglutide (Rybelsus, Ozempic tablets, Wegovy tablets): the peptide that survives the stomach
You'll get: Semaglutide comes as three daily tablets: Rybelsus and Ozempic tablets for diabetes, and Wegovy tablets for weight.
The three semaglutide tablets (Rybelsus, Ozempic, Wegovy), why they are not interchangeable, the 25 mg Wegovy tablet, trial results, and side effect rates.
Updated September 4, 202603 · Agents
FeaturedTirzepatide (Mounjaro, Zepbound): the GIP and GLP-1 dual agonist
You'll get: Tirzepatide is a once a week shot sold as Mounjaro for type 2 diabetes and Zepbound for weight and sleep apnea.
Tirzepatide (Mounjaro, Zepbound): how it differs from semaglutide, every FDA approval from 2022 to the 2026 heart indication, dosing, trials, side effects.
Updated September 4, 202604 · Agents
Liraglutide (Victoza, Saxenda): the once-daily GLP-1 analogue
You'll get: Liraglutide is a once a day shot, sold as Victoza for type 2 diabetes and Saxenda for weight.
Liraglutide, the daily GLP-1 shot: Victoza for diabetes since 2010, Saxenda for weight since 2014, label dosing, trial results, and side effect rates.
Updated September 4, 202605 · Agents
Dulaglutide (Trulicity): the antibody-fused weekly GLP-1
You'll get: Trulicity is a once a week shot approved for type 2 diabetes in adults and children aged 10 and up.
Trulicity, the weekly GLP-1 shot for type 2 diabetes: approvals since 2014, label dosing, heart trial results, and side effect rates from the label.
Updated September 4, 202606 · Agents
Exenatide (Byetta, Bydureon, Bydureon BCise): the first GLP-1 receptor agonist
You'll get: Exenatide, sold as Byetta and Bydureon, was the first GLP-1 drug, approved in 2005 for type 2 diabetes.
Exenatide (Byetta, Bydureon) started the GLP-1 class in 2005: approvals, dosing, trial results, side effect rates, and why all three are now discontinued.
Updated September 4, 202607 · Agents
Lixisenatide (Adlyxin, Soliqua): the short-acting daily GLP-1
You'll get: Adlyxin is a once a day shot for type 2 diabetes that works mainly on the meal right after the injection.
Adlyxin, the short acting daily GLP-1 shot for type 2 diabetes: 2016 approvals, label dosing, trial results, side effect rates, and its role in Soliqua.
Updated September 4, 202608 · Agents
Albiglutide (Tanzeum): the withdrawn weekly GLP-1
You'll get: Albiglutide was sold as Tanzeum, a once a week shot for type 2 diabetes, approved in 2014.
Tanzeum, a weekly GLP-1 shot approved in 2014 and later pulled from sale by its maker: how it worked, its trial results, and its side effect rates.
Updated September 4, 202609 · Agents
FeaturedOrforglipron (Foundayo): the first small-molecule GLP-1 receptor agonist
You'll get: Foundayo is a once a day tablet approved in April 2026 for weight loss in adults; it is not approved for diabetes.
Foundayo, the daily GLP-1 pill approved April 2026 for weight loss: no food rule, how it differs from semaglutide tablets, trial results and side effects.
Updated September 4, 202610 · Agents
Retatrutide: the GIP, GLP-1 and glucagon triple agonist (investigational)
You'll get: Retatrutide is not FDA approved and is still in trials; anything sold under that name is unapproved and untested.
Retatrutide, Lilly's weekly three signal shot. Not FDA approved. What glucagon adds, the 24 percent phase 2 result, and what is not yet known.
Updated September 4, 202611 · Agents
Survodutide: the glucagon and GLP-1 dual agonist (investigational)
You'll get: Survodutide is not FDA approved and is still in trials, so it has no label and cannot be prescribed.
Survodutide, a weekly GLP-1 plus glucagon shot. Not FDA approved. Phase 2 and 3 weight results, the liver disease program, and why the placebo arm matters.
Updated September 4, 202612 · Agents
CagriSema (cagrilintide and semaglutide): the amylin combination (investigational)
You'll get: CagriSema is not FDA approved and is still being tested, so it has no label and cannot be prescribed.
CagriSema pairs semaglutide with an amylin copy in one weekly shot. Not FDA approved. What amylin adds, REDEFINE trial results, and how it compares.
Updated September 4, 202613 · Agents
Mazdutide: the GLP-1 and glucagon dual agonist from China (investigational in the US)
You'll get: Mazdutide is not FDA approved and has no US application; its trials so far were run in China.
Mazdutide, a weekly GLP-1 plus glucagon shot tested in China. Not FDA approved. GLORY trial weight results, side effects at 9 mg, and its US status.
Updated September 4, 2026